Articles By Estel Grace Masangkay

  1. Lilly's Cyramza Approved By FDA For Aggressive NSCLC 12/17/2014

    The U.S. Food and Drug Administration (FDA) announced that it has approved the expanded use of Eli Lilly’s drug Cyramza (ramucirumab) as treatment for metastatic non-small cell lung cancer (NSCLC).

  2. Sanofi Pasteur MSD's Gardasil 9 For HPV Approved By FDA 12/15/2014

    The U.S. Food and Drug Administration (FDA) has approved Sanofi Pasteur MSD’s Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) to prevent diseases caused by nine types of Human Papillomavirus (HPV).

  3. Alexion Posts Data For Soliris In aHUS At ASH 2014 12/15/2014

    Alexion presented findings for its drug Soliris (eculizumab) in the treatment of atypical hemolytic uremic syndrome (aHUS), as well as new data regarding medical care for patients with aHUS and paroxysmal nocturnal hemoglobinuria (PNH) at the 56th Annual Meeting of the American Society of Hematology (ASH) held in San Francisco this month.

  4. Merck, Amgen Begin Combo Immunotherapy Trial In Melanoma 12/12/2014

    Merck and its partner Amgen announced the initiation of the clinical trial investigating the combination immunotherapy of Amgen’s talimogene laherparepvec with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab), in patients with regionally or distantly metastatic melanoma.

  5. Lilly, Incyte Post Top-Line Phase 3 Data For Baricitinib In RA 12/12/2014

    Eli Lilly & Co. and its partner Incyte announced positive top-line results from the late-stage trial of baricitinib in moderately-to-severely active rheumatoid arthritis (RA).

  6. MorphoSys Posts Positive Phase 2 Data For MOR208 In NHL 12/11/2014

    Therapeutic antibody specialist MorphoSys announced positive mid-stage results for its proprietary drug lead MOR208 as treatment for relapsed or refractory Non-Hodgkin's Lymphoma (NHL).

  7. Roche To Present Data For Gazyvaro And MabThera At ASH 2014 12/10/2014

    Roche announced that it will present new data for two of its approved hematology drugs Gazyvaro (obinutuzumab) and MabThera/Rituxan (rituximab), along with other medicines at the 56th American Society of Hematology (ASH) Annual Meeting in San Francisco.

  8. Merck Reports Strong Phase 1B Data For Keytruda In r/r cHL 12/10/2014

    Merck announced strong early study results for Keytruda (pembrolizumab) as treatment for relapsed/refractory classical Hodgkin Lymphoma (cHL) patients who have failed or are ineligible for transplant and whose disease has developed following treatment with brentuximab vedotin.

  9. Incyte's Jakafi OK'd By FDA For Blood Cancer PV 12/9/2014

    Delaware-based biopharmaceutical firm Incyte announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Jakafi (ruxolitinib) as treatment for patients with uncontrolled polycythemia vera (PV) who are intolerant to or have had an inadequate response to hydroxyurea.

  10. EMA Accepts Pharmacyclics' Application For Imbruvica In WM 12/8/2014

    Pharmacyclics reported that its Type II variation application for Imbruvica (ibrutinib) as treatment for Waldenstrom's Macroglobulinemia (WM) has been accepted by the European Medicines Agency (EMA) for review.